CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326 · cited 1×
“Global estimates suggest that almost 1 billion people aged 30–69 years have OSA (defined as an apnea–hypopnea index (AHI >5/h)); of these, 425 million have moderate to severe disease (AHI ≥15/h) [1].”
BackgroundSelf-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Diagnosis and Management of Obstructive Sleep Apnea: A Review
Gottlieb, D. J., & Punjabi, N. M. (2020) · JAMA · doi:10.1001/jama.2020.3514 · Cited by 1,482 · cited 1×
“Furthermore, the fact that CPAP has not had any significant effects on the cardiovascular event rate in randomized clinical trials to date [10,11,23] means that the benefits of this treatment approach in unselected patient groups may be difficult to justify [29].”
BackgroundObstructive sleep apnoea syndrome
Lévy, P., Kohler, M., McNicholas, W. T., Barbé, F., McEvoy, R. D., Somers, V. K., Lavie, L., & Pépin, J.-L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.15 · Cited by 1,235
Self-citationBarbé, F., Durán-Cantolla, J., Sánchez-de-la-Torre, M., Martínez-Alonso, M., Carmona, C., Barceló, A., Chiner, E., Masa, J. F., Gonzalez, M., Marín, J. M., et al. (2012) · JAMA · doi:10.1001/jama.2012.4366 · Cited by 792 · cited 3×
“Clinical trial data show that fewer than 50% of patients are using CPAP for >4 h/night after 1 year [9], but this threshold of device usage may be essential for the benefits of therapy to be realized [10,11].”
BackgroundPeker, Y., Glantz, H., Eulenburg, C., Wegscheider, K., Herlitz, J., & Thunström, E. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0088oc · Cited by 756 · cited 3×
“Clinical trial data show that fewer than 50% of patients are using CPAP for >4 h/night after 1 year [9], but this threshold of device usage may be essential for the benefits of therapy to be realized [10,11].”
BackgroundMartínez-García, M.-A., Capote, F., Campos-Rodríguez, F., Lloberes, P., Díaz de Atauri, M. J., Somoza, M., Masa, J. F., González, M., Sacristán, L., Barbé, F., et al. (2013) · JAMA · doi:10.1001/jama.2013.281250 · Cited by 685
Sánchez-de-la-Torre, M., Sánchez-de-la-Torre, A., Bertran, S., Abad, J., Duran-Cantolla, J., Cabriada, V., Mediano, O., Masdeu, M. J., Alonso, M. L., Masa, J. F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30271-1 · Cited by 522
The different clinical faces of obstructive sleep apnoea: a cluster analysis
Ye, L., Pien, G. W., Ratcliffe, S. J., Björnsdottir, E., Arnardottir, E. S., Pack, A. I., Benediktsdottir, B., & Gislason, T. (2014) · European Respiratory Journal · doi:10.1183/09031936.00032314 · Cited by 474 · cited 1×
“When patients with OSA were classified into three distinct clusters, those in the “minimally symptomatic” group had the highest probability of having comorbid hypertension and cardiovascular disease [22].”
BackgroundMartínez-García, M. A., Soler-Cataluña, J. J., Ejarque-Martínez, L., Soriano, Y., Román-Sánchez, P., Illa, F. B., Canal, J. M. M., & Durán-Cantolla, J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1341oc · Cited by 390
Metadata
- Authors
- Pépin, J.-L., Bailly, S., Rinder, P., Adler, D., Szeftel, D., Malhotra, A., Cistulli, P., Benjafield, A., Lavergne, F., Josseran, A., Tamisier, R., Hornus, P., & on behalf of the medXcloud Group
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-03-01
- Volume
- 10
- Issue
- 5
- Pages
- 936
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3134953171
- Cited by
- 167
- References
- 14
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. https://app.cochat.ai/papers/10.3390/jcm10050936
- The paper
- Pépin, J.-L., Bailly, S., Rinder, P., Adler, D., Szeftel, D., Malhotra, A., Cistulli, P., Benjafield, A., Lavergne, F., Josseran, A., Tamisier, R., Hornus, P., & on behalf of the medXcloud Group. (2021). CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10050936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.